The AACR will present the 2026 AACR Award for Lifetime Achievement in Cancer Research to Dr. James P. Allison, Fellow of the AACR Academy, during the AACR Annual Meeting 2026
The AACR will present the 2026 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the AACR Annual Meeting 2026
An updated trial analysis presented at AACR 2026 showed that the investigational KRAS G12D inhibitor zoldonrasib demonstrated clinical activity with a favorable safety profile in previously treated KRAS G12D‑mutant NSCLC patients
The AACR will honor leaders from government and the advocacy community with awards for distinguished service in support of cancer research at the AACR Annual Meeting 2026
Meeting co‑chairs Dr. Paul Mischel and Dr. Alice Shaw share the themes, challenges, and scientific momentum shaping this year’s must‑attend event
The multicancer early detection platform was developed based on methylation of cell-free DNA
The peptide-based vaccine induces a T cell-dependent response
The epigenomic signature is evident prior to CD19-targeted CAR T-cell treatment
Latinos are also more likely to be diagnosed with this cancer type
Researchers have developed risk prediction algorithms for many forms of cancer as a result of recent breakthroughs in AI
Researchers have demonstrated that the adverse effects of combination therapy could be predicted
The identification of this genetic variant could help select lung cancer patients who may be at risk of more severe autoimmune side effects
An mRNA vaccine was combined with CAR T-cells that target tumor cells expressing the CLDN6 antigen
Study shows majority of pediatric cancer deaths are in lower- and middle-income countries
The RACE act has led to increased requirements for approval of recent pediatric cancer drugs
A study has shown that prostate-specific antigen (PSA) screening accuracy could be improved by accounting for genetic factors
the CAR-T therapy showed early signs of efficacy both as a monotherapy and in combination with CARVac in patients with testicular and other solid tumors
NK cells complexed with a CD30/CD16A bispecific antibody may help patients with advanced lymphoma
Two-year follow up of the CodeBreaK100 clinical trial demonstrated prolonged tumor responses and a favorable safety profile
Patients with recurrent lesions genetically distinct from the primary tumor may require different treatment
AACR President David A. Tuveson will chair the symposium titled: Aging, Stress, and Cancer.
AACR President David A. Tuveson says clinicians will be ready and waiting before the cancer appears in the future
AACR and CRUK, two of the biggest cancer research committees around the globe to join force to aid the development of cancer therapeutics
The AACR and the UBS oncology impact fund aim to use the new funding gift program to propel breakthroughs in cancer research and therapeutics
